U.S. Markets closed

Cardiovascular Systems Unveils Favorable LIBERTY 360 Data

Zacks Equity Research

Medical device manufacturer Cardiovascular Systems, Inc. CSII recently released one-year data from its LIBERTY 360° clinical study in a late-breaking presentation at the 2017 Amputation Prevention Symposium (AMP) in Chicago. LIBERTY 360° is a prospective, observational, multi-center post-market study. The study was based on more than 1,200 patients at 51 sites across the U.S., including 501 patients with claudication, 603 patients with critical limb ischemia (CLI) and 100 patients with the most severe form of CLI.

The study examined the acute and long-term clinical and economic outcomes of peripheral vascular interventions (PVI) in peripheral artery disease (PAD) patients. LIBERTY 360° included all FDA-approved endovascular devices to treat PAD.

The 12-month data from this study demonstrated that peripheral endovascular intervention marked improvement across all Ruthetford Classes along with high freedom from major adverse events. To be precise, LIBERTY 360°showed that PVI can help prevent amputation for patients with PAD, specifically CLI.

As per the company’s press release, around 18 million Americans suffer from PAD, which is caused by the accumulation of plaque in peripheral arteries reducing blood flow. We believe that the company is adopting appropriate strategic moves to capture the niche market.

In this regard to note, the company recently received FDA approval for radial access Diamondback 360 Peripheral Orbital Atherectomy Device to treat PAD. The commercial availability is expected in the beginning of calendar year 2018.

Some notable stocks in the broader industry are Haemonetics Corporation HAE, Stryker Corporation SYK and Lantheus Holdings, Inc. LNTH.

Zacks' 10-Minute Stock-Picking Secret

Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.

But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month.

Learn the secret >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Stryker Corporation (SYK) : Free Stock Analysis Report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII) : Free Stock Analysis Report
Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report
To read this article on Zacks.com click here.